<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04955730</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-20561</org_study_id>
    <nct_id>NCT04955730</nct_id>
  </id_info>
  <brief_title>NPWT in Patients Undergoing Surgical Procedures for Management of GI Malignancies</brief_title>
  <official_title>Randomized Trial of Prolonged Use of Negative Pressure Wound Therapy in Patients Undergoing Surgical Procedures for the Management of Gastrointestinal Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized trial will use a Negative Pressure Wound Therapy device or standard wound&#xD;
      closure, in participants with gastrointestinal neoplasms, to measure the rate of surgical&#xD;
      site infections&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants, investigators and statisticians will be blinded to treatment randomization but the surgeons will not.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Surgical Site Infection - Superficial Incisional</measure>
    <time_frame>30 days post operation</time_frame>
    <description>Investigators will measure rate of Surgical Site Infection (SSI) of participants who received Superficial Incisions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surgical Site Infection - Deep Incisional</measure>
    <time_frame>30 days post operation</time_frame>
    <description>Investigators will measure rate of Surgical Site Infection (SSI) of participants who received Deep Incisions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surgical Site Infection - Organ/Space Incisional</measure>
    <time_frame>30 days post operation</time_frame>
    <description>Investigators will measure rate of Surgical Site Infection (SSI) of participants who received Organ/Space Incisions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Return to Intended Oncologic Therapy (RIOT)</measure>
    <time_frame>Up to 12 months after surgery</time_frame>
    <description>Investigators will measure number of participants who returned to their intended oncologic therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Initiation of Planned Oncologic Therapy</measure>
    <time_frame>Up to 12 months after surgery</time_frame>
    <description>Investigators will measure time to initiation planned therapy from the surgery date to initiation date of planned oncologic therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Surgical Wound Infection</condition>
  <arm_group>
    <arm_group_label>NPWT - Negative Pressure Wound Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Negative Pressure Wound Therapy (NPWT) after surgery and wear the NPWT until postop day 3. NPWT dressing will be removed and a new NPWT will be replaced until Postop day 7, where NPWT dressing will be removed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Wound Therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will receive standard of care wound therapy after surgery. Postop day 3, dressings will be removed and new sterile dressings will be applied if needed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Negative Pressure Wound Therapy</intervention_name>
    <description>Negative Pressure Wound Therapy is a single use NPWT that produces a negative pressure at -80 mmHg. Participants will have their fascia and skin closed in the same manner as the control arm participants, and will wear the NPWT dressing for 7 days after surgery.</description>
    <arm_group_label>NPWT - Negative Pressure Wound Therapy</arm_group_label>
    <other_name>PICO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled surgical procedure for the management of gastrointestinal cancer&#xD;
&#xD;
          -  Have a surgical wound bigger than 5cm&#xD;
&#xD;
          -  Skin wound closed by primary intention with either: Staples covered by sterile Telfa速&#xD;
             and Tegaderm速 or Medipore速 OR Dermal or subcuticular sutures covered by Octil速&#xD;
&#xD;
          -  Provision of signed and dated informed consent form&#xD;
&#xD;
          -  Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Wound considered dirty (class IV per wound classification)&#xD;
&#xD;
          -  Wound left for closure by secondary intention&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  Pregnancy. Pregnancy status is confirmed per protocol the day of surgery in the&#xD;
             preoperative space by urine pregnancy test in patient younger than 65 and with intact&#xD;
             uterus. Pregnant patient will be excluded from this study&#xD;
&#xD;
          -  History or current diagnosis of any medical or psychological condition that in the&#xD;
             Investigator's opinion, might interfere with the subject's ability to participate in&#xD;
             the study or the inability to obtain informed consent because of psychiatric or&#xD;
             complicating medical problems&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose M Pimiento, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Anaya, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose Pimiento, MD</last_name>
    <phone>813-745-1277</phone>
    <email>Jose.Pimiento@moffitt.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Anaya, MD</last_name>
    <phone>813-745-6898</phone>
    <email>Daniel.Anaya@moffitt.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Kryliouk</last_name>
      <phone>813-745-6688</phone>
      <email>Victoria.Kryliouk@moffitt.org</email>
    </contact>
    <contact_backup>
      <last_name>Jose Pimiento, MD</last_name>
      <phone>813-745-1277</phone>
      <email>Jose.Pimiento@moffitt.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jose Pimiento, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Anaya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael J Schell, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Green, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julian Sanchez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sean Dineen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Dessureault, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pamela J Hodul, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mokenge Malafa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Fleming, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seth Felder, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Denbo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://moffitt.org/clinicaltrialssearch?DiseaseSite=&amp;q=20561</url>
    <description>Moffitt Cancer Center Clinical Trial Search</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wound Infection</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

